

Mona Bafadhel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7177936/publications.pdf>

Version: 2024-02-01

107
papers

6,413
citations

126708

33
h-index

69108

77
g-index

112
all docs

112
docs citations

112
times ranked

6224
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterogeneity of IPF exacerbations. <i>Lancet Respiratory Medicine</i> , 2022, 10, e3.	5.2	0
2	Chronic Obstructive Pulmonary Disease Exacerbations: Do All Roads Lead to Rome?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1125-1126.	2.5	2
3	Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 545-556.	5.2	30
4	Ethnicity-based differences in asthma diagnostic thresholds. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1124.	2.0	1
5	Blood eosinophils to guide inhaled maintenance therapy in a primary care COPD population. <i>ERJ Open Research</i> , 2022, 8, 00606-2021.	1.1	12
6	Chronic obstructive pulmonary disease. <i>Lancet</i> , 2022, 399, 2227-2242.	6.3	228
7	Predictive modeling of COPD exacerbation rates using baseline risk factors. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211073.	1.0	10
8	Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1488-1502.	2.5	107
9	Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. <i>Thorax</i> , 2021, 76, 188-195.	2.7	73
10	Recruiting patients to a digital self-management study whilst in hospital for a chronic obstructive pulmonary disease exacerbation: A feasibility analysis. <i>Digital Health</i> , 2021, 7, 205520762110208.	0.9	1
11	Infection, inflammation and intervention: mechanistic modelling of epithelial cells in COVID-19. <i>Journal of the Royal Society Interface</i> , 2021, 18, 20200950.	1.5	22
12	Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus. <i>International Journal of COPD</i> , 2021, Volume 16, 321-332.	0.9	18
13	Benefit/Risk Profile of Single-Inhale Triple Therapy in COPD. <i>International Journal of COPD</i> , 2021, Volume 16, 499-517.	0.9	17
14	High serum G-CSF characterises neutrophilic COPD exacerbations associated with dysbiosis. <i>ERJ Open Research</i> , 2021, 7, 00836-2020.	1.1	3
15	A Comprehensive Analysis of the Stability of Blood Eosinophil Levels. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1978-1987.	1.5	19
16	Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 763-772.	5.2	301
17	Inhaled budesonide for early treatment of COVID-19 – Authors' reply. <i>Lancet Respiratory Medicine</i> , 2021, 9, e61.	5.2	7
18	Antimicrobial Peptides SLPI and Beta Defensin-1 in Sputum are Negatively Correlated with FEV1. <i>International Journal of COPD</i> , 2021, Volume 16, 1437-1447.	0.9	6

#	ARTICLE	IF	CITATIONS
19	Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. International Journal of COPD, 2021, Volume 16, 1755-1770.	0.9	30
20	Predicting treatment outcomes following an exacerbation of airways disease. PLoS ONE, 2021, 16, e0254425.	1.1	3
21	Eosinophilic inflammation, coronavirus disease 2019, and asthma. Annals of Allergy, Asthma and Immunology, 2021, 127, 278.	0.5	2
22	Research priorities for exacerbations of COPD. Lancet Respiratory Medicine, the, 2021, 9, 824-826.	5.2	28
23	A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. European Respiratory Journal, 2021, 58, 2004522.	3.1	4
24	Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet, The, 2021, 398, 843-855.	6.3	204
25	Renaming COPD exacerbations: the UK respiratory nursing perspective. BMC Pulmonary Medicine, 2021, 21, 299.	0.8	2
26	Biomarkers in COPD. , 2021, , .		1
27	Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals. International Journal of COPD, 2021, Volume 16, 3009-3016.	0.9	3
28	Improved COVID-19 outcomes in a large non-invasive respiratory support cohort despite emergence of the alpha variant. BMJ Open Respiratory Research, 2021, 8, e001044.	1.2	3
29	Discordant diagnostic criteria for pneumonia in COPD trials: a review. European Respiratory Review, 2021, 30, 210124.	3.0	8
30	High-dose budesonide for early COVID-19 " Authors' reply. Lancet, The, 2021, 398, 2147-2148.	6.3	0
31	Sputum microbiomic clustering in asthma and chronic obstructive pulmonary disease reveals a <i>Haemophilus</i> predominant subgroup. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 808-817.	2.7	33
32	An expert consensus framework for asthma remission as a treatment goal. Journal of Allergy and Clinical Immunology, 2020, 145, 757-765.	1.5	144
33	Resistome analyses of sputum from COPD and healthy subjects reveals bacterial load-related prevalence of target genes. Thorax, 2020, 75, 8-16.	2.7	18
34	Exacerbations of chronic obstructive pulmonary disease: time to rename. Lancet Respiratory Medicine, the, 2020, 8, 133-135.	5.2	13
35	Successful awake proning is associated with improved clinical outcomes in patients with COVID-19: single-centre high-dependency unit experience. BMJ Open Respiratory Research, 2020, 7, e000678.	1.2	44
36	Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?. Lancet Respiratory Medicine, the, 2020, 8, 846-847.	5.2	48

#	ARTICLE	IF	CITATIONS
37	A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. <i>Trials</i> , 2020, 21, 718.	0.7	25
38	Is it time to give up on "self-management" of COPD exacerbations?. <i>European Respiratory Journal</i> , 2020, 55, 1902102.	3.1	0
39	Evaluating the sensitivity and specificity of NEATstik technology compared to an activity-based immunoassay in sputum samples from participants with COPD. <i>European Respiratory Journal</i> , 2020, 55, 1902412.	3.1	0
40	Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000577.	1.2	15
41	Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 660-671.	2.5	62
42	Detection of Cell-Dissociated Non-Typeable <i>Haemophilus influenzae</i> in the Airways of Patients with Chronic Obstructive Pulmonary Disease. <i>International Journal of COPD</i> , 2020, Volume 15, 1357-1365.	0.9	0
43	The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1441-1443.	2.5	14
44	Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis. <i>Respiratory Research</i> , 2020, 21, 17.	1.4	16
45	The CICERO (Collaboration In COPD Exacerbations) Clinical Research Collaboration. <i>European Respiratory Journal</i> , 2020, 55, 2000079.	3.1	10
46	Neutrophil elastase as a biomarker for bacterial infection in COPD. <i>Respiratory Research</i> , 2019, 20, 170.	1.4	53
47	Building toolkits for COPD exacerbations: lessons from the past and present. <i>Thorax</i> , 2019, 74, 898-905.	2.7	34
48	Blood eosinophil count and GOLD stage predict response to maintenance azithromycin treatment in COPD patients with frequent exacerbations. <i>Respiratory Medicine</i> , 2019, 154, 27-33.	1.3	4
49	Benralizumab for the Prevention of COPD Exacerbations. <i>New England Journal of Medicine</i> , 2019, 381, 1023-1034.	13.9	180
50	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. <i>Annals of the American Thoracic Society</i> , 2019, 16, 29-39.	1.5	11
51	What will Happen in the World of COPD 2030?. <i>Turkish Thoracic Journal</i> , 2019, 20, 153-257.	0.2	0
52	COPD exacerbations: transforming outcomes through research. <i>Lancet Respiratory Medicine</i> , 2018, 6, 172-174.	5.2	3
53	Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. <i>Lancet Respiratory Medicine</i> , 2018, 6, 117-126.	5.2	298
54	Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2027-2036.e12.	1.5	124

#	ARTICLE	IF	CITATIONS
55	Investigating blood eosinophil count thresholds in patients with COPD. <i>Lancet Respiratory Medicine</i> , 2018, 6, 823-824.	5.2	5
56	Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of COPD?: PRO. <i>Medical Sciences (Basel, Switzerland)</i> , 2018, 6, 74.	1.3	7
57	Symptomatic COPD: is it time for triple therapy?. <i>Lancet Respiratory Medicine</i> , 2018, 6, 728-729.	5.2	1
58	Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma. <i>Mucosal Immunology</i> , 2018, 11, 1408-1419.	2.7	46
59	Eosinophils in COPD: just another biomarker?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 747-759.	5.2	160
60	Alternatives to induced sputum for identifying inflammatory subtypes of asthma. <i>Respirology</i> , 2017, 22, 624-625.	1.3	3
61	Precision medicine in airway diseases: moving to clinical practice. <i>European Respiratory Journal</i> , 2017, 50, 1701655.	3.1	151
62	Blood eosinophil count and exacerbation risk in patients with COPD. <i>European Respiratory Journal</i> , 2017, 50, 1700761.	3.1	64
63	Eosinophils in COPD: are we nearly there yet?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 913-914.	5.2	12
64	Comparison of the peripheral blood eosinophil count using near-patient testing and standard automated laboratory measurement in healthy, asthmatic and COPD subjects. <i>International Journal of COPD</i> , 2017, Volume 12, 2771-2775.	0.9	9
65	Investigating the role of pentraxin 3 as a biomarker for bacterial infection in subjects with COPD. <i>International Journal of COPD</i> , 2017, Volume 12, 1199-1205.	0.9	14
66	Microbiome balance in sputum determined by PCR stratifies COPD exacerbations and shows potential for selective use of antibiotics. <i>PLoS ONE</i> , 2017, 12, e0182833.	1.1	25
67	Impaired P2X1 Receptor-Mediated Adhesion in Eosinophils from Asthmatic Patients. <i>Journal of Immunology</i> , 2016, 196, 4877-4884.	0.4	13
68	Chronic obstructive pulmonary disease: management of chronic disease. <i>Medicine</i> , 2016, 44, 310-313.	0.2	2
69	Are COPD and cardiovascular disease fundamentally intertwined?. <i>European Respiratory Journal</i> , 2016, 47, 1307-1309.	3.1	6
70	Blood Eosinophils and Outcomes in Severe Hospitalized Exacerbations of COPD. <i>Chest</i> , 2016, 150, 320-328.	0.4	125
71	Lung microbiome dynamics in COPD exacerbations. <i>European Respiratory Journal</i> , 2016, 47, 1082-1092.	3.1	330
72	Exome-wide analysis of rare coding variation identifies novel associations with COPD and airflow limitation in <i>MOCS3</i> , <i>IFIT3</i> and <i>SERPINA12</i> . <i>Thorax</i> , 2016, 71, 501-509.	2.7	22

#	ARTICLE	IF	CITATIONS
73	Association Between Pathogens Detected Using Quantitative Polymerase Chain Reaction With Airway Inflammation in COPD at Stable State and Exacerbations. <i>Chest</i> , 2015, 147, 46-55.	0.4	74
74	Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. <i>International Journal of COPD</i> , 2015, 10, 1075.	0.9	61
75	Toll-like receptor 9 dependent interferon- γ release is impaired in severe asthma but is not associated with exacerbation frequency. <i>Immunobiology</i> , 2015, 220, 859-864.	0.8	9
76	Biological clustering supports both "Dutch" and "British" hypotheses of asthma and chronic obstructive pulmonary disease. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 63-72.e10.	1.5	111
77	Fractional exhaled nitric oxide in chronic obstructive pulmonary disease. , 2015, , .		3
78	Investigation the role of pentraxin-3 in the innate immune system in patients with COPD. , 2015, , .		0
79	The identification of distinct immunophenotypical subgroups in a COPD patient population based on predominating T-lymphocyte subsets. , 2015, , .		0
80	The detection of free-living H. influenzae in the airways of patients with COPD. , 2015, , .		0
81	Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. <i>International Journal of COPD</i> , 2014, 9, 179.	0.9	12
82	Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2014, 9, 975.	0.9	12
83	Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. <i>European Respiratory Journal</i> , 2014, 44, 789-791.	3.1	141
84	Respimat vs HandiHaler: a lesson in asking the right question. <i>The Prescriber</i> , 2014, 25, 7-8.	0.1	0
85	Flu vaccine reduces risk of adverse CV events in high-risk patients. <i>The Prescriber</i> , 2014, 25, 34-34.	0.1	0
86	Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. <i>Lancet Respiratory Medicine</i> , the, 2014, 2, 891-901.	5.2	248
87	<i>Aspergillus fumigatus</i> during stable state and exacerbations of COPD. <i>European Respiratory Journal</i> , 2014, 43, 64-71.	3.1	110
88	COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. <i>BMC Pulmonary Medicine</i> , 2014, 14, 112.	0.8	62
89	Eosinophilic Chronic Obstructive Pulmonary Disease is Not Associated with Helminth Infection or Exposure. <i>Journal of Pulmonary & Respiratory Medicine</i> , 2014, 04, .	0.1	0
90	Elevated Sputum Interleukin-5 and Submucosal Eosinophilia in Obese Individuals with Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 657-663.	2.5	198

#	ARTICLE	IF	CITATIONS
91	Exhaled nitric oxide and blood eosinophilia: Independent markers of preventable risk. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 828-829.	1.5	34
92	Genome-Wide Association Study Identifies Novel Loci Associated With Reversibility To A^2 Agonist In Severe Asthma Subjects. , 2012, , .		0
93	Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 48-55.	2.5	499
94	Routine processing procedures for isolating filamentous fungi from respiratory sputum samples may underestimate fungal prevalence. <i>Medical Mycology</i> , 2012, 50, 433-438.	0.3	94
95	Genome-Wide Association Study Identifies Novel Loci Associated With Forced Expiratory Volume In One Second (FEV1) As A Percent Of Predicted In Severe Asthma Subjects. , 2012, , .		0
96	Chronic obstructive pulmonary disease: management of chronic disease. <i>Medicine</i> , 2012, 40, 262-266.	0.2	1
97	Acute Exacerbations of Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2011, 184, 662-671.	2.5	847
98	Procalcitonin and C-Reactive Protein in Hospitalized Adult Patients With Community-Acquired Pneumonia or Exacerbation of Asthma or COPD. <i>Chest</i> , 2011, 139, 1410-1418.	0.4	145
99	Procalcitonin vs Clinical and Chest Film Findings to Diagnose Community-Acquired Pneumonia in Patients With Acute Asthma or Acute Exacerbations of Chronic Bronchitis: Response. <i>Chest</i> , 2011, 140, 1668.	0.4	0
100	Serum Procalcitonin and Infective Exacerbations of Asthma: Response. <i>Chest</i> , 2011, 140, 1390-1391.	0.4	0
101	The Role of CT Scanning in Multidimensional Phenotyping of COPD. <i>Chest</i> , 2011, 140, 634-642.	0.4	96
102	Visual vs Automated Assessment of Emphysema: Response. <i>Chest</i> , 2011, 140, 1385.	0.4	1
103	Expression of the T Helper 17-Associated Cytokines IL-17A and IL-17F in Asthma and COPD. <i>Chest</i> , 2010, 138, 1140-1147.	0.4	331
104	The Risk Factors That Identify With Airflow Obstruction And Exacerbations In Severe Asthma. , 2010, , .		0
105	The Influence Of Body Mass Index Upon Emphysema In COPD. , 2010, , .		0
106	Body Mass and Fat Mass in Refractory Asthma: An Observational 1 Year Follow-Up Study. <i>Journal of Allergy</i> , 2010, 2010, 1-9.	0.7	7
107	The Role Of A Peripheral Blood Eosinophil Count As A Biomarker For A Sputum Eosinophilia In COPD Exacerbations. , 2010, , .		1